Dishman Carbogen Peer Comparison

NSE: DCAL | BSE: 540701

₹181.83

₹3.49 (1.96%)

As on 01-Sep-2026 15:31IST

Market cap

₹2,855 Cr

Revenue (TTM)

₹2,901 Cr

P/E Ratio

176.7

P/B Ratio

0.4

Div. Yield

0 %

Edit

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Market cap (₹ Cr)	2,855	273	217	41	9
Revenue (₹ Cr)	2,901	138	85	55	0
Net Profit (₹ Cr)	16.16	-9.39	12.82	-2.86	0.02
Net Margin (%)	0.55	-6.66	6.38	-5.15	9.72
RoE (%)	0.29	-9.20	20.84	-16.06	0.53
Price to Earnings	176.67	--	16.96	--	421.96
Price-To-Book	0.43	2.89	6.78	0.44	2.25

Income Statement (₹ Cr)

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Operating Revenue	2,901.49	137.73	84.56	55.10	0.22
Total Income	2,950.84	141.01	92.53	55.46	0.22
Total Expenditure	2,416.46	140.53	86.29	34.09	0.18
EBITDA	485.03	-2.80	-1.73	21.01	0.04
Depreciation	348.02	8.36	0.01	11.51	0.00
EBIT	137.01	-11.16	-1.74	9.50	0.03
Interest	168.51	3.32	0.18	5.58	0.00
Other Income	49.35	3.29	7.97	0.36	0.00
Exceptional Items	-2.84	0.00	0.00	-0.61	0.00
Profit before Tax	15.01	-11.19	6.06	3.67	0.03
Provision for Tax	-1.15	-1.80	0.16	6.53	0.01
Profit after Tax	16.16	-9.39	5.90	-2.86	0.02

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Shareholder's Funds	6,676.90	92.39	31.00	93.16	3.93
Minority Interest	0.00	0.49	0.00	0.00	0.00
Non-Current Liabilities	2,929.36	29.81	0.00	55.04	0.00
Current Liabilities	2,317.05	53.90	5.24	30.23	0.32
Total Liabilities	9,986.90	176.20	36.48	143.23	4.36

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Non-Current Assets	8,580.12	88.99	0.00	149.74	1.55
Current Assets	2,842.10	63.28	23.77	28.42	2.70
Total Assets	9,986.90	176.20	36.48	143.23	4.36
Total Debt*	2,083.91	38.00	0.00	54.03	0.00
Net Current Assets	525.05	9.38	18.53	-1.82	2.38
Contingent Liabilities	423.42	26.88	74.49	--	--

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Cash From Operating Activities	375.23	1.90	-16.37	11.83	0.03
Cash Flow from Investing Activities	-192.21	-11.80	22.21	-15.84	0.01
Cash from Financing Activities	-102.09	5.29	-3.24	3.90	--
Net Cash Inflow / Outflow	80.93	-4.60	2.60	-0.11	0.04

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
ROCE (%)	2.31	10.01	13.63	12.63	11.87
ROE (%)	0.29	-9.20	20.84	-16.06	0.53
ROA (%)	0.15	-5.35	16.23	-1.78	0.49
EBIT Margin (%)	4.72	-8.10	-2.05	17.24	14.35
Net Margin (%)	0.55	-6.66	6.38	-5.15	9.72
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Revenue Growth (%)	0.20	-2.60	-100.00	12.34	-72.27
EBIT Growth (%)	-50.39	-203.38	67.89	-22.16	-90.43
Net Profit Growth (%)	-84.49	-222.82	81.10	-133.81	-91.46
EPS Growth (%)	-85.24	-218.89	81.10	-230.45	-91.46
Book Value Growth (%)	3.63	76.48	331.34	30.20	10.05

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Price / Earnings	150.41	-29.98	38.78	-2.73	436.36
Price / Book Value	0.42	2.87	7.14	0.45	2.32
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	8.97	-113.68	-130.23	4.49	260.52
Market Cap (₹ Cr)	3,411.88	360.30	--	58.31	17.90

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Debt to Equity	0.23	0.25	0.00	0.50	0.00
Short term debt to equity ratio	0.11	0.14	--	0.15	--
Current Ratio	1.23	1.17	4.54	0.94	8.40
Quick Ratio	0.79	0.92	4.54	0.67	7.52
Interest Coverage	1.09	-2.37	35.64	1.66	2,845.31

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Debtors to sales (%)	23.19	25.44	0.26	21.32	1,073.15
Asset Turnover	0.26	0.79	2.33	0.34	0.05
Receivable days	77.38	92.33	--	90.11	1,026.01
Inventory Days	120.02	29.04	--	64.77	122.93
Payable days	172.74	88.82	--	64.32	554.30
Cash Conversion Cycle	24.66	32.55	--	90.56	594.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.